AbbVie Reports First-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Abbvie (ABBV) PT Raised to $129 at BMO Capital
May 3, 2021 7:31 AM EDTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $129.00 (from $127.00) while maintaining an Outperform rating.
The analyst commented, "1Q was high quality with solid top-line beat (mainly from Aesthetics and Immunology) dropping to bottom line, and improved diversification of... More
AbbVie (ABBV) Tops Q1 EPS by 12c, Offers FY Guidance
April 30, 2021 7:43 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.95, $0.12 better than the analyst estimate of $2.83. Revenue for the quarter came in at $12.94 billion versus the consensus estimate of $12.76 billion.
GUIDANCE:
AbbVie sees FY2021 EPS of $12.37-$12.57, versus the consensus of... More
